Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a “dietary-achievable” or “pharmacological” dose: what are the implications for anticancer activity?

American Journal of Clinical Nutrition(2020)10.1093/ajcn/nqaa414Source: DataRank Database

Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a “dietary-achievable” or “pharmacological” dose: what are the implications for anticancer activity? is a research paper published in American Journal of Clinical Nutrition (2020). On theSindex it has a DataRank of 0. It has been cited 15 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access15 citations

Download PDF

Cite:

Linked data & code

eudract

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (9 grants)Impact (FWCI 0.78)OA: hybridTopics (46)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Edwina N. Scott,Robert G. Britton ORCID,Emma Parrott,Ted Ognibene ORCID,Michael Malfatti ORCID

Live enrichment

PubMed:33675348 PMC:PMC8106746 OpenAlex:https://openalex.org/W3133611895

Cancer Research UK

Grant: C325/A13101

Leicester Experimental Cancer Medicine Centre

Grant: C325/A15575

Leicester Experimental Cancer Medicine Centre

Grant: C10604/A25151

U.S. Department of Energy

Grant: DE-AC52-07NA27344

Biomedical Technology Research Resources

Grant: P41GM103483

NIGMS NIH HHS

Grant: R24 GM137748

Cancer Research UK

Grant: 13101

National Institute of General Medical Sciences

NIH

FWCI

0.78

Citation Percentile

0.7%

Citation Trend

2022

2023

2024

2025

2026

hybridLicense: cc-by

journalhttps://www.sciencedirect.com/science/article/pii/S0002916522006876/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S0002916522006876/pdf

publisherhttps://api.elsevier.com/content/article/PII:S0002916522006876?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0002916522006876?httpAccept=text/plain

publisherhttp://academic.oup.com/ajcn/article-pdf/113/5/1115/37905779/nqaa414.pdf

Fields of Study

Sirtuins and Resveratrol in MedicineBioactive natural compoundsPARP inhibition in cancer therapyAdministration, OralAntioxidantsCarbon RadioisotopesCell Line, TumorDietDose-Response Relationship, DrugDrug Administration RoutesHumansIsotope LabelingMaleProstateProstatic NeoplasmsResveratrol

MeSH Terms

ResveratrolAdministration, OralAntioxidantsCarbon RadioisotopesDietDose-Response Relationship, DrugDrug Administration RoutesHumansIsotope LabelingMaleProstateProstatic NeoplasmsCell Line, Tumor

Keywords

ResveratrolProstateProstate cancerBioavailabilityPharmacokineticsPharmacologyOral administrationProstate biopsyMedicineChemistryCancerInternal medicineMetabolismTissue distributionCancer PreventionAccelerator Mass SpectrometryWindow Trial

Sustainable Development Goals

SDG 0: Good health and well-being

Distribution and metabolism of [14C]-resveratrol in human prostate tissue after oral administration of a “dietary-achievable” or “pharmacological” dose: what are the implications for anticancer activity?

FAIR Checklist

Authors (9)

Funding (9 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)